Long-time ICIS member and supporter, Thomas Wynn, PhD has, for many years, been a vocal advocate for the engagement of Pfizer specifically, and the biopharma industry more broadly, in the Cytokine Society and our annual conference. Tom’s selection as the Howard A. Young Distinguished Service awardee recognizes his appreciation of the need for a pipeline of well-trained cytokine biologists that can play critical roles in drug development and his belief in the importance of the ICIS mission. He has gone out of his way to ensure that the partnership between Pfizer and the ICIS remains strong.
Dr. Wynn is Vice President and Head of Discovery in Pfizer’s Inflammation and Immunology research unit. He is responsible for leading target identification and validation and ensuring sustainable project entry to preclinical development for I&I. He ensures innovation in the end-to-end I&I pipeline by collaborating with external key opinion leaders and by working closely with the business development team. He joined Pfizer in 2017 and since 2019 he has also served as the scientific director of Pfizer’s global postdoctoral program.
Before joining Pfizer, Dr. Wynn was senior Investigator and Chief of the Immunopathogenesis Section at the National Institute of Allergy and Infectious Diseases, NIH in Bethesda, MD, where he led a team of scientists studying type-2 cytokine driven inflammatory disease and fibrosis. Tom earned his Ph.D. from the Department of Medical Microbiology and Immunology at the University of Wisconsin, in Madison, Wisconsin and completed his postdoctoral training in the laboratory of parasitic diseases at NIAID/NIH. He has published over 250 research papers, reviews, and book chapters in many top tier journals and is included among Clarivate’s list of “Highly Cited Researchers” in the field of Immunology.
